Diagnosis and Treatment of Community‐Acquired Pneumonia

Campbell, Sam; Marrie, Tom

doi:10.1002/9781444303674.ch11

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the guidelines recently released by the National Health and Medical Commission indicated that SARS-CoV-2 severe cases generally impart severe pneumonia accompanied by difficulty in breathing after one week of illness [ 11 , 12 ]. Severe cases quickly progress to ARDS, septic shock, and multiple organ dysfunction syndrome (MODS), which are challenging to manage medically [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients

Alzahrani

Saadeldin

Ahmad

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing lethal acute respiratory disease emerged in December 2019. The World Health Organization named this disease “COVID-19” and declared it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) and their exosomes (MSCs-Exo), which are isolated from allogenic bone marrow stem cells, significantly lower the risk of alveolar inflammation and other pathological conditions associated with distinct lung injuries. For example, in acute respiratory distress syndrome (ARDS) and pneumonia patients, MSCs-Exo and MSCs provide similar healing properties and some clinical trials have used cell-based inhalation therapy which show great promise. MSCs and MSCs-Exo have shown potential in clinical trials as a therapeutic tool for severely affected COVID-19 patients when compared to other cell-based therapies, which may face challenges like the cells’ sticking to the respiratory tract epithelia during administration. However, the use of MSCs or MSCs-Exo for treating COVID-19 should strictly adhere to the appropriate manufacturing practices, quality control measurements, preclinical safety and efficacy data, and the proper ethical regulations. This review highlights the available clinical trials that support the therapeutic potential of MSCs or MSCs-Exo in severely affected COVID-19 patients.

show abstract

Section: Introductionmentioning

confidence: 99%